Fernández ÁJD

Idioma: Español
Referencias bibliográficas: 28
Paginas: 1-6
Archivo PDF: 394.54 Kb.

FRAGMENTO

En el año 2020 se cumplen 110 años de que James Herrick, un médico de Chicago, describiera las células falciformes en una muestra de sangre de Walter Clement Noel, estudiante de odontología de Granada que presentaba dolor recurrente y anemia.El término sickle cell anemia se adoptó posterior a ese informe.
La anemia falciforme es el defecto monogénico más común en el mundo, que provoca un trastorno multisistémico con episodios agudos y progresión a la afectación crónica de órganos.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Herrick JB. Peculiar elongated and Sickle-shaped red blood corpuscles in a case of severe anemia. Arch Inter Med. 1910;6:517.

2. Watson J, Staham AW, Billelo FP. The significance of the paucity of sickle cells in newborn negro infants. Am J Med Sci. 1948;215:419-23.

3. Pauling L, Itano HA, Itano S, Singer J, Wells IC. Sickle cell anemia a molecular disease. Science. 1949;110(2865):543-8.

4. Neel JV. The inheritance of sickle cell anemia. Science. 1949;110(2846):64

5. Beet EA. The genetics of the sickle-cell trait in a Bantu tribe. Ann Eugen. 1949;14(4):279-84.

6. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J. 1954;1(4857):290-4.

7. Benz EJ. Genotypes and phenotypes. Another lesson from the hemoglobinopathies. N Engl J Med. 2004;351(15):1490-2.

8. Gaston M, Smith J, Gallagher D, et al. Recruitment in the cooperative study of sickle cell disease (CSSCD). Control Clin Trials.1987;8:131s-40s.

9. Pagnier J, Mears JG, Dunda-Belkhodja O, Schaefer-Rego KE, Beldjord C, Nagel RL. Evidence for the multicentric origin of the sickle cell hemoglobin gene in Africa. Proc Natl Acad Sci USA. 1984;81(6):1771-3.

10. Johnson FL, Look AT, Gockerman J, Ruggiero MR, Dalla-Pozza L, Billings FT. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med. 1984;311(12):780-3.

11. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314(25):1593-9.

12. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22.

13. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998;339:5-11.

14. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769-78.

15. Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicenter, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661-70.

16. Ware RE, Helms RW. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012; 19:3925-32.

17. DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699-710.

18. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA. 2003; 289:1645-51.

19. Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, et al. Hydroxycarbamide in very young children with sickle cellanaemia: A multicenter, randomized, controlled trial (BABY HUG). Lancet. 2011;377:1663-72.

20. Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361:2309-17.

21. 21 . Bolanos-Meade J, Fuchs EJ, Luznik L, Gamper CJ, Jones RJ, Brodsky RA, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285-91

22. 22 . U.S. Food & Drug Administration. FDA approves new treatment for sickle cell disease. 2017 July 17 [accessed 01/02/2020]. Available in:Available in:http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm566084.htm

23. Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429-39.

24. Ataga KI, Desai PC. Advances in new drug therapies for the management of sickle cell disease. Expert Opin Orphan Drugs. 2018;6(5):329-43.

25. Shet AS, Thein SL. A growing population of older adults with sickle cell disease. Clin Geriatr Med. 2019;35:349-67.

26. Gardner K, Douiri A, Drasar E, Allman M, Mwirigi A, Awogbade M, et al. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016;128(10):1436-8.

27. Chaturvedi S, DeBaun MR. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years. Am J Hematol. 2016;91(1):5-14.

28. Demirci S, Uchida N, Tisdale JF. Gene therapy for sickle cell disease: an update Cytotherapy. 2018;20(7):899-910.